IsoPet®: Advanced Injectable Cancer Treatment for Animals
IsoPet® by Vivos Inc. (OTCQB: RDGL) offers a cutting-edge, injectable cancer therapy for pets using Yttrium-90. This revolutionary treatment represents a significant advancement in veterinary oncology, providing a highly targeted approach to cancer treatment that minimizes damage to healthy tissues while effectively targeting tumors.
IsoPet® leverages the precision of Yttrium-90, a powerful radionuclide, encapsulated within a hydrogel delivery system to ensure that the radiation is confined strictly to the tumor site. This methodology not only enhances the efficacy of the treatment but also significantly reduces the potential side effects typically associated with conventional radiation therapy.
Vivos Inc Stock Price Today | OTC RDGL Live Ticker – Investing.com
Developed with the goal of improving the quality of life for pets suffering from cancer, IsoPet® has demonstrated promising results in preclinical trials, showing effectiveness in treating various types of tumors in animals. By offering a localized and minimally invasive treatment option, IsoPet® stands out as a beacon of hope for pet owners and veterinarians seeking innovative solutions for cancer care.
Furthermore, the technology behind IsoPet® parallels advancements made for human treatments with RadioGel™, which has garnered attention as a breakthrough device by the FDA, expediting its review process for clinical trials.
How IsoPet® Works
IsoPet® involves injecting a hydrogel containing yttrium-90 phosphate microparticles directly into tumors. This targeted approach delivers localized radiation, reducing harm to surrounding healthy tissues. Preclinical trials have demonstrated its efficacy, including successful treatments of feline sarcomas at Washington State University and canine soft tissue sarcomas at the University of Missouri.
Expansion Efforts in 2024
In 2024, Vivos Inc. has focused on expanding IsoPet® clinics across the U.S. However, the rollout has been slower than expected, with only one new clinic opening mid-year. Despite this, the goal remains to make IsoPet® more accessible and affordable, overcoming resistance within the veterinary community.
Current IsoPet® Clinics
IsoPet® treatments are currently available at several veterinary clinics:
- Vista Veterinary Hospital – Kennewick, WA
- University of Missouri – Columbia, MO
- Johns Hopkins University – Baltimore, MD
- New England Equine Practice – Patterson, NY
- Myhre Equine Clinic – Rochester, NH
- Hopkinton Animal Hospital – Weare, NH
- Indian Creek Veterinary Hospital – Fort Wayne, IN
- University of Wisconsin – Madison, WI
Future Clinic Locations
Vivos Inc. plans to certify additional clinics in Texas, California, and Washington, reflecting their commitment to making IsoPet® treatments more widely accessible. This strategic expansion is designed to reduce travel distances for pet owners, ensuring that more pets can benefit from IsoPet®’s advanced cancer therapy without the need for long, stressful journeys. By establishing new clinics in these key states, Vivos Inc. aims to cater to a larger geographic area, meeting the growing demand for innovative and effective cancer treatments in pets.
Additionally, these new locations will facilitate faster and more convenient access to IsoPet® for veterinarians and pet owners, ultimately contributing to improved treatment outcomes and quality of life for animal patients. As part of this expansion, Vivos Inc. is also focused on raising awareness and providing training to veterinary professionals in these regions, ensuring that the highest standards of care are maintained across all IsoPet® clinics.
Road Trip and Outreach
To raise awareness and educate the veterinary community about IsoPet®, Vivos Inc. is actively participating in major veterinary conferences, including those hosted by the California Veterinary Medical Association (PACVET), the Veterinary Cancer Society (VCS), American Association of Zoo Veterinarians (AAZV), American Association of Equine Practitioners (AAEP), and Vivos Inc. plans to attend the Cowboy Christmas convention during National Finals Rodeo in Las Vegas to wrap up 2024. These prestigious events provide invaluable platforms for Vivos Inc. to showcase the benefits and effectiveness of IsoPet® to a wide audience of veterinary professionals and pet parents.
By attending and presenting at these conferences, Vivos Inc. aims to foster a deeper understanding of IsoPet®’s technology and its application in treating various animal cancers. These interactions facilitate direct engagement with veterinarians, allowing them to learn firsthand about the clinical successes and practical applications of IsoPet®. Moreover, these events serve as opportunities for Vivos Inc. to network with industry leaders.
Vivos Inc. and the IsoPet Division have kicked off a several month long Pet Cancer Awareness Campaign targeting small animal, equine and exotic animal veterinary clinics. The cancer campaign underscores Vivos Inc.’s commitment to hands-on outreach. The journey kicked off in Kennewick, WA on July 1st, followed by visits to Seattle, Portland and surrounding strategic locations throughout Washington and Oregon the first two weeks of July. The team will then head to San Francisco for the PACVET conference from July 11th to 14th, before continuing to locations throughout California for the remainder of July. August will include subsequent stops in Arizona, New Mexico, Oklahoma, Texas and the team will take their initiative to Florida.
In September, the road trip will cover strategic cities along the eastern coast, heading north towards Toronto for the American Association of Zoo Veterinarians (AAZV) conference from September 24th to 26th. This leg includes visits to Buffalo, Cleveland, Columbus, Louisville, Nashville, and more. The final phase in October sees the team returning to Florida for the Veterinary Cancer Society (VCS) Conference in Orlando from October 17th to 19th, and wrapping up with visits to additional Florida cities and Atlanta, GA.
By traveling to these regions and attending local veterinary meetings, Vivos Inc. can directly address the concerns and questions of veterinary practitioners, building trust and credibility within the community. This proactive approach ensures that more veterinarians are equipped with the knowledge and skills to implement IsoPet® in their practices, ultimately leading to broader adoption of this innovative treatment.
Additionally, these outreach efforts include workshops and training sessions aimed at demonstrating the proper use and administration of IsoPet®. Through detailed presentations and live demonstrations, Vivos Inc. provides veterinary teams with the tools they need to confidently incorporate IsoPet® into their treatment protocols. By prioritizing education and support, Vivos Inc. is paving the way for IsoPe® to become a standard option in veterinary cancer care, significantly improving outcomes for pets diagnosed with cancer.
A Promising Future for Veterinary Cancer Care
IsoPet® represents a major advancement in veterinary cancer treatment, providing a targeted and effective solution for pet tumors. Despite a gradual expansion, Vivos Inc. remains committed to making this therapy accessible nationwide. As Vivos Inc. continues to increase IsoPet® availability across U.S. veterinary clinics, more pets will benefit from this innovative, life-saving treatment. This effort aims to make IsoPet® more accessible and affordable, setting new standards in veterinary oncology and offering hope to countless animal patients and their owners.
About Vivos Inc.
Vivos Inc. has developed an Yttrium-90-based injectable Precision Radionuclide Therapy™ medical device to treat tumors in animals (IsoPet®) and humans (RadioGel®). Using the company’s proprietary hydrogel technology, PRnT™ uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. This allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers.
Vivos Inc. Announces IDE Submission for RadioGel™ (tradersque.com)
RadioGel® Technology
RadioGel® is a hydrogel liquid containing yttrium-90 phosphate microparticles, administered directly into a tumor. After injection, it gels within the tumor interstitial spaces to keep the radiation sources in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area, minimizing adverse effects on normal organs and tissues. The short half-life of RadioGel® ensures that more than 90% of its therapeutic radiation is delivered within 10 days, allowing for outpatient procedures without risk to family members.
IsoPet® for Veterinary Use
IsoPet® uses the same technology as RadioGel® for treating animals. It has been tested successfully on feline sarcoma at Washington State University and on canine soft tissue sarcomas at the University of Missouri. The FDA has classified IsoPet® as a medical device and does not require pre-market approval for veterinary use, allowing for revenue generation through sales to university hospitals and private clinics.
Vivos Inc. | RadioGel™ | IsoPet® – (OTCMKTS: RDGL)
Meet the Visionaries Behind Vivos Inc.
Meet the innovative minds driving Vivos Inc. forward in the fight against cancer. Our dedicated team combines expertise, passion, and cutting-edge technology to revolutionize cancer treatment. Learn more about our leaders and their groundbreaking work by visiting Meet The Team | RadioGel™
Disclaimer: This article includes paid promotions. We may receive compensation for promoting certain securities. This could influence our content. Please perform your own due diligence and consult with a financial advisor before making any investment decisions.
